Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Johnson and Johnson
AstraZeneca
Boehringer Ingelheim
Baxter

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,850,229

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,850,229
Title:Compounds and compositions as protein kinase inhibitors
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Inventor(s): Huang; Shenlin (San Diego, CA), Jin; Xianming (San Ramon, CA), Liu; Zuosheng (San Diego, CA), Poon; Daniel (Piedmont, CA), Tellew; John (La Jolla, CA), Wan; Yongqin (Irvine, CA), Wang; Xing (San Diego, CA), Xie; Yongping (San Diego, CA)
Assignee: Array BioPharma, Inc. (Boulder, CO)
Application Number:15/179,385
Patent Claims: 1. A method of treating melanoma in a subject in need thereof, the method comprising: (a) detecting a mutant BRAF kinase in the melanoma; and (b) orally administering to said subject a therapeutically effective amount of: (i) a pharmaceutical composition comprising methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan- -2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutical composition comprising a MEK inhibitor.

2. The method of claim 1, wherein said pharmaceutical composition comprising methyl N-[(2 S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl- )-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate or a pharmaceutically acceptable salt thereof and said pharmaceutical composition comprising said MEK inhibitor are administered as a non-fixed combination.

3. The method of claim 2, wherein said pharmaceutical composition comprising methyl N-[(2 S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl- )-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate or a pharmaceutically acceptable salt thereof and said pharmaceutical composition comprising said MEK inhibitor are administered sequentially.

4. The method of claim 3, wherein the melanoma is melanoma having a B-Raf V600E mutation.

5. The method of claim 4, wherein the MEK inhibitor is selected from: AS703026; MSC1936369B; GSK1120212; AZD6244; PD-0325901; ARRY-438162; RDEA119; GDC0941; GDC0973; TAK-733; RO5126766; and XL-518.

6. The method of claim 5, wherein the MEK inhibitor is ARRY-438162.

7. The method of claim 3, wherein said pharmaceutical composition comprising methyl N-[(2 S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl- )-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate or a pharmaceutically acceptable salt thereof is formulated as a capsule.

8. The method of claim 6, wherein said pharmaceutical composition comprising methyl N-[(2 S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl- )-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate or a pharmaceutically acceptable salt thereof is formulated as a capsule.

9. The method of claim 2, wherein said pharmaceutical composition comprising methyl N-[(2 S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl- )-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate or a pharmaceutically acceptable salt thereof and said pharmaceutical composition comprising said MEK inhibitor are administered concurrently.

10. The method of claim 9, wherein the melanoma is melanoma having a B-Raf V600E mutation.

11. The method of claim 10, wherein the MEK inhibitor is selected from: AS703026; MSC1936369B; GSK1120212; AZD6244; PD-0325901; ARRY-438162; RDEA119; GDC0941; GDC0973; TAK-733; RO5126766; and XL-518.

12. The method of claim 11, wherein the MEK inhibitor is ARRY-438162.

13. The method of 9, wherein said pharmaceutical composition comprising methyl N-[(2 S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl- )-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate or a pharmaceutically acceptable salt thereof is formulated as a capsule.

14. The method of claim 12, wherein said pharmaceutical composition comprising methyl N-[(2 S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl- )-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate or a pharmaceutically acceptable salt thereof is formulated as a capsule.

15. The method of claim 4, wherein said melanoma is metastatic melanoma.

16. The method of claim 15, wherein the MEK inhibitor is selected from: AS703026; MSC1936369B; GSK1120212; AZD6244; PD-0325901; ARRY-438162; RDEA119; GDC0941; GDC0973; TAK-733; RO5126766; and XL-518.

17. The method of claim 16, wherein the MEK inhibitor is ARRY-438162.

18. The method of claim 10, wherein said melanoma is metastatic melanoma.

19. The method of claim 18, wherein the MEK inhibitor is selected from: AS703026; MSC1936369B; GSK1120212; AZD6244; PD-0325901; ARRY-438162; RDEA119; GDC0941; GDC0973; TAK-733; RO5126766; and XL-518.

20. The method of claim 19, wherein the MEK inhibitor is ARRY-438162.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKinsey
Boehringer Ingelheim
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.